Last reviewed · How we verify
Benzeneformic Acid (benzoic acid)
At a glance
| Generic name | benzoic acid |
|---|---|
| Drug class | Nitrogen Binding Agent [EPC] |
| Target | Nicotinate phosphoribosyltransferase |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
- Symptoms of irritative voiding
- Relief of local symptoms in lower urinary tract infections
- Relief of urinary tract symptoms from diagnostic procedures
Common side effects
Key clinical trials
- Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention (PHASE2)
- Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy (NA)
- Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced (PHASE2)
- Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal (PHASE2)
- Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy (PHASE2)
- Hyperglycemia in Patients with Stroke and Indication of Enteral Nutrition (NA)
- Elimination of Odor and Treatment of Malodorous Recalcitrant Wounds by Using Supraz and PRP-FG Versus Standard of Care (PHASE2,PHASE3)
- A Clinical Efficacy Study of MsChief Personal Lubricant in Healthy Female Subjects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benzeneformic Acid CI brief — competitive landscape report
- Benzeneformic Acid updates RSS · CI watch RSS
- portfolio CI